Free Trial
NASDAQ:ACRS

Aclaris Therapeutics (ACRS) Stock Price, News & Analysis

Aclaris Therapeutics logo
$1.32 -0.12 (-7.99%)
As of 02:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Aclaris Therapeutics Stock (NASDAQ:ACRS)

Key Stats

Today's Range
$1.32
$1.45
50-Day Range
$1.08
$2.11
52-Week Range
$0.95
$5.17
Volume
221,086 shs
Average Volume
886,727 shs
Market Capitalization
$143.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.67
Consensus Rating
Buy

Company Overview

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aclaris Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

ACRS MarketRank™: 

Aclaris Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 646th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aclaris Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Aclaris Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aclaris Therapeutics is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aclaris Therapeutics is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aclaris Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Aclaris Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.09% of the float of Aclaris Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aclaris Therapeutics has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Aclaris Therapeutics has recently decreased by 34.78%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Aclaris Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aclaris Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.09% of the float of Aclaris Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aclaris Therapeutics has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Aclaris Therapeutics has recently decreased by 34.78%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Aclaris Therapeutics has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Aclaris Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 4 people have searched for ACRS on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aclaris Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.40% of the stock of Aclaris Therapeutics is held by insiders.

  • Percentage Held by Institutions

    98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Aclaris Therapeutics' insider trading history.
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Stock News Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More Headlines

ACRS Stock Analysis - Frequently Asked Questions

Aclaris Therapeutics' stock was trading at $2.48 on January 1st, 2025. Since then, ACRS shares have decreased by 46.2% and is now trading at $1.3350.
View the best growth stocks for 2025 here
.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.03. The biotechnology company earned $4.35 million during the quarter, compared to analysts' expectations of $8.31 million. Aclaris Therapeutics had a negative net margin of 136.65% and a negative trailing twelve-month return on equity of 40.26%.

Top institutional shareholders of Aclaris Therapeutics include Assenagon Asset Management S.A. (0.63%), Alps Advisors Inc. (0.07%) and Cannon Global Investment Management LLC (0.03%). Insiders that own company stock include Braden Michael Leonard, Neal Walker, Anand Mehra, Andrew N Schiff, Joseph Monahan, James Loerop, Douglas J Manion and Kevin Balthaser.
View institutional ownership trends
.

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aclaris Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Netflix (NFLX) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/06/2024
Today
5/05/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACRS
Employees
100
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$11.67
High Stock Price Target
$20.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+710.2%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-88,480,000.00
Net Margins
-136.65%
Pretax Margin
-138.00%

Debt

Sales & Book Value

Annual Sales
$18.72 million
Price / Cash Flow
N/A
Book Value
$2.22 per share
Price / Book
0.65

Miscellaneous

Free Float
66,859,000
Market Cap
$155.92 million
Optionable
Optionable
Beta
0.42

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:ACRS) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners